Table 1: Clinical characteristics of the study population.

CharacteristicsData

Patients (number)26
Recipient age (years): mean (SD)40 (13.5)
Donor age (years): mean (SD)40 (15)
Recipient sex, male/female, ( , (%))15 (57.7)/11 (42.3)
Donor sex, male/female ( , (%))20 (76.9)/6 (23.1)
Disease ( , (%))
  AML5 (19.2)
  ALL2 (7.6)
  CML3 (11.5)
  Non-Hodgkin’s lymphoma4 (15.3)
  MM4 (15.3)
  Aplasia2 (7.6)
  MDS3 (11.5)
  PNH3 (11.5)
Conditioning regimen ( , (%))
  NMA13 (50)
  MA13 (50)
Stem cell source ( , (%))
  Bone marrow12 (46.1)
  Peripheral blood14 (53.8)
Pretransplant HCMV donor serostatus/recipient ( , (%))
  D+/R+14 (53.8)
  D−/R+10 (38.4)
  D−/R−2 (7.7)
HCMV replication after transplant ( , (%))
  Yes15 (57.7)
  No11 (42.3)
HLA matching ( , (%))
  Matched related18 (69.2)
  Matched unrelated6 (23.1)
  Mismatched unrelated2 (7.7)
GVHD ( , (%))
  Yes11 (42.3)
  No15 (57.7)
Corticosteroids ( , (%))
  Yes18 (69.2)
  No8 (30.8)
Frequency of CD8+ T cells (mean, SD)35.1 (14.8)
Frequency of HCMV-specific CD8+ T cells (mean, SD)1.4 (2.1)
Frequency of HCMV-specific CD8+ T cells naive (mean, SD)6.7 (11.3)
Frequency of HCMV-specific CD8+ T cells CD28+ (mean, SD)30 (23.2)

AML: acute myeloid leukemia; ALL: acute lymphatic leukemia; CML: chronic myeloid leukemia; MM: multiple myeloma; MDS: myelodysplastic syndrome; PNH: paroxysmal nocturnal hemoglobinuria; NMA: non-myeloablative; MA: myeloablative. D: donor; R: recipient; HCMV: human cytomegalovirus; GVHD: graft-versus-host disease. Naive cells are CD45RA+CCR7+.